NCT04485585 - A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

August 16, 2020

Study Completion Date

August 26, 2020

Conditions

Benign Prostatic Hyperplasia (BPH)Overactive Bladder

Interventions

DRUG

BR9006-1

* Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose

DRUG

BR9006-2

"* Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose"

Trial Locations (1)

13520

CHA Bundang Medical Center, CHA University, Seongnam-si